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     INTRODUCTION 
  Melioidosis is a serious infectious disease caused by the 
Gram-negative bacterium   Burkholderia pseudomallei . 1,  2   This 
organism is present in the environment in a defined geographic 
distribution including much of south and east Asia, northern 
Australia, and areas of South America, where infection is 
thought to be acquired after bacterial inoculation, ingestion, 
or inhalation.  1–  3   The clinical presentation is highly variable 
and ranges from a mild localized infection to acute fulminant 
sepsis with widespread bacterial dissemination.  1,  2   The  clinical 
diagnosis of melioidosis is notoriously inaccurate, and diag-
nostic confirmation relies on culture of   B. pseudomallei . 4   Lack 
of microbiological services in many of the countries predicted 
to be affected by melioidosis is likely to result in gross under-
reporting of cases and an underestimate of the global burden 
of this infection. 
  Melioidosis is a leading cause of bacterial sepsis in northeast 
Thailand.  5–  8   Childhood infection accounts for around 10% of 
cases overall in this setting, and acute suppurative parotitis 
accounts for one-third of pediatric cases.  9   Adjacent to north-
east Thailand is Laos to the east and southeast and Cambodia 
to the south. Melioidosis was first reported from Laos in 2001 
after the development of a diagnostic microbiology laboratory 
at Mahosot Hospital, Vientiane,  10   and   B. pseudomallei   was 
subsequently isolated from the surrounding environment.  11  
  B. pseudomallei   has also been isolated from rice paddies in 
Siem Reap province in northwest Cambodia,  12   and a recent 
report of two cases of melioidosis in adults from southern 
Cambodia has confirmed the presence of melioidosis in the 
indigenous population.  13   A seroprevalence study of children 
presenting to a hospital in Siem Reap detected antibodies 
to   B. pseudomallei   in 16% of cases,  12   but melioidosis has not 
been detected previously in this pediatric population. Here, 
we report the identification of 39 cases of melioidosis at the 
Angkor Hospital for Children in Siem Reap, the first reported 
cases in Cambodian children. Their identification followed the 
introduction of diagnostic microbiology capabilities, highlight-
ing one of the many benefits of laboratory strengthening in 
this region. 
   MATERIALS AND  METHODS 
  Setting  and  patients.     The study was conducted at the Angkor 
Hospital for Children (AHC), an non-governmental organiza-
tion (NGO)-funded teaching hospital in Siem Reap, situated 
in the province of Siem Reap, northwest Cambodia. The AHC 
provides free outpatient, inpatient, emergency, surgical, medical, 
ophthalmological, and dental care, and it maintains 50 inpatient 
beds spread across high-, medium-, and low-intensity care areas. 
The outpatient department sees an average of approximately 
400 children each day from an unrestricted catchment area. 
  The study protocol was reviewed and approved by the 
Ethical Review Board of the Angkor Hospital for Children. 
A laboratory-based study was conducted between October 
2005 and December 2008 to identify children presenting to 
inpatient or outpatient departments with one or more micro-
biological samples positive for   B. pseudomallei .  A  retrospec-
tive review of case records was performed at the end of this 
period to collect information on age, gender, area of residence, 
sample(s) positive for   B. pseudomallei  , known sites of organ 
involvement, results of laboratory and radiological investiga-
tions, antimicrobial treatment, procedures, duration of hospi-
tal stay, outcome at hospital discharge, and details of follow-up. 
Sites of infection were established based on a record of history 
and examination findings in the medical notes together with 
investigation reports and procedure notes. 
  Melioidosis was classified as localized or disseminated. 
Localized infection was defined as a single, discrete, culture-
positive focus of infection in the absence of a positive blood 
culture or clinical and/or microbiological evidence of dissemi-
nation to a second site. Disseminated infection was defined as 
the presence of infection in two or more discrete body sites 
and/or the presence of   B. pseudomallei   in blood. 
   Microbiological  methods.     Specimens from patients with 
suspected melioidosis were processed using standard laboratory 
procedures with the addition of Ashdown selective agar for 
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culture of samples from colonized sites.  14   Identification of 
  B. pseudomallei   was made on the basis of Gram stain, resistance 
to gentamicin and colistin, a positive latex agglutination test,  15,  16  
and the API 20NE profile.  16  Susceptibility testing was performed 
by disk diffusion assay for ceftazidime, meropenem, amoxicillin-
clavulanate, and doxycycline and by E-test for trimethoprim-
sulfamethoxazole (TMP-SMX). Isolates were stored in Tryptone 
Soya broth (TSB) with       20% glycerol at −80°C. 
   Molecular  characterization  of   B. pseudomallei  .    Genomic 
DNA was extracted from a 1-mL overnight culture of 
  B. pseudomallei   with an optical density of 1.0 at 600 nm 
using the High Pure PCR Template Preparation Kit (Roche 
Applied Science, Mannheim, Germany). Multilocus sequence 
typing (MLST) was performed as described pre  viously.  17  
Sequence-type (ST) assignment was based on the sequence of 
the alleles at each locus of seven housekeeping genes using 
the MLST database (  www.mlst.net  ). Sequences that were 
not in the database were checked by resequencing, and then 
assigned as new alleles and deposited in the MLST allele 
database. 
  MLST was performed on 39   B. pseudomallei   isolates cul-
tured from children with melioidosis described in this study 
and 14   B. pseudomallei   isolates cultured previously from soil 
in Cambodia, of which 12 were isolated in Siem Reap province 
during 2006  12   and 2 were isolated in Phnom Penh in south-
ern Cambodia in 1996. MLST data on   B. pseudomallei   iso-
lates from Thailand that had originated in our laboratory and/
or had been reported previously  17–  19   were downloaded from 
 www.mlst.net   ( N   = 462). Neighbor-joining trees were recon-
structed using the two-parameter method of distance estima-
tion as implemented in MEGA 4.0. 
    RESULTS 
  Overview  of  cases.     Thirty-nine cases of culture-proven 
melioidosis were identified in children presenting to the AHC 
between October 2005 and December 2008. No case clustering 
was observed, and cases were distributed throughout the study 
period as follows: 2005 (3 months),   N   = 2; 2006,   N   = 9; 2007, 
  N   = 13; 2008,   N   = 14. The geographic location of the village 
or town in which the cases lived is shown in   Figure 1  . These 
observations suggest that infections were sporadic and not 
related to one or more outbreaks. 
    Summary data for the 39 cases are shown in   Table 1  . Median 
age was 7.8 years (range = 1.6–16.2 years), and the male/female 
ratio was 1:1.6. Four children (10%) had pre-existing condi-
tions that may have pre-disposed them to infection: juvenile 
rheumatoid arthritis (1 case), thalassemia and renal disease 
(1 case), Pott’s disease (tuberculosis of the spine; 1 case), and 
chronic otitis media with   B. pseudomallei   meningitis (1 case). 
            Infection was defined as localized in 27 children (69%) and 
disseminated in 12 children (31%); 21 of 27 localized infec-
tions (78%) were in the region of the head and neck, includ-
ing 15 cases of acute suppurative parotitis. The disseminated 
infection group included nine children with blood cultures 
positive for   B. pseudomallei   in association with clinical and 
radiographic evidence of pneumonia (  N   = 2), clinical meningi-
tis and a history of chronic suppurative otitis media for whom 
the cerebrospinal fluid (CSF) culture       was negative (  N   = 1), or 
no other identified focus of infection (  N   = 6) and three chil-
dren who did not have a positive blood culture with multiple 
skin pustules (  N   = 1), mastoiditis and abscesses in the liver and 
spleen on ultrasound (  N   = 1), or pneumonia associated with 
respiratory failure and septic shock (  N   = 1). This last case with 
respiratory secretions positive for   B. pseudomallei   had neither 
positive blood cultures nor a second site of infection, but was 
classified as having disseminated infection based on the sys-
temic response and severity of illness. 
  Eight of thirty-nine children (21%) died a median of 2 days 
after admission (range, day of admission to day 23), all of 
whom were in the disseminated infection group (8/12; 67%). 
Seven deaths were attributable to melioidosis, whereas the 
eighth case had both tuberculosis meningitis and   B. pseudo-
mallei   pneumonia and had responded to 14 days of ceftazi-
dime by the time of death on day 23 because of intracranial 
hypertension secondary to tuberculosis meningitis. A posi-
tive blood culture was associated with a very poor prognosis, 
and death occurred in 7 of 9 cases (78%). Both children with 
a total white blood cell (WBC) count of less than 5.0 × 10  9 /L 
(1.6 × 10  9  /L and 2.6 × 10  9  /L, respectively) died. 
  All 39   B. pseudomallei   isolates were susceptible to ceftazi-
dime, meropenem, amoxicillin-clavulanate, TMP-SMX, and 
doxycycline, the most common drugs used for the treatment 
of adult melioidosis. 
   Clinical  management.     Eleven children (28%) were treated 
in the outpatient department alone for localized   B. pseudo-
mallei   infection (parotid abscess, 4; superficial soft-tissue 
abscess, 7). Incision and drainage of pus was performed in 
10 of these cases, and all 11 cases were prescribed one or 
more antimicrobial drugs for a median of 4 weeks (range, 
5 days to 17 weeks; IQR = 1–6 weeks). The antimicrobial 
drugs prescribed were amoxicillin-clavulanate alone (  N   = 2), 
amoxicillin-clavulanate in combination with TMP-SMX 
(  N   = 2), amoxicillin-clavulanate in combination with cipro-
floxacin (  N   = 2), or cloxacillin alone (  N   = 5). Six of eleven 
children did not attend for follow-up, and their outcome was 
unknown. Five children followed-up for a period of 4–17 weeks 
were documented as having resolution of clinical features of 
infection. 
  Twenty-eight children (72%) were admitted to the AHC; 
16 cases had localized infection, and 12 cases had disseminated 
infection. Duration of admission for the 20 in-patient survivors 
ranged from 1 to 31 days (median = 15.5 days; IQR = 12.0–
17.5 days). Management is presented separately for localized 
and disseminated infection. 
      Admitted with localized infection (  N   = 16).    All  cases  had 
an incision and drainage procedure. Fifteen cases were started 
on empiric parenteral antimicrobial drugs (ceftriazone or 
cloxacillin) for suspected localized bacterial infection at the 
time of admission. The remaining case was a child with a 
pharyngeal abscess who was treated with incision and drainage 
under general anesthetic and discharged the following day 
with a 7-day course of oral cloxacillin for suspected   S. aureus  
infection before culture results were available. This child 
was lost to follow-up. The remaining 15 cases were still in 
the hospital when the   B. pseudomallei   culture result became 
available, and therapy was changed to ceftazidime (  N   = 14) 
or parenteral amoxicillin-clavulanate (  N   = 1) for a median of 
11 days (range = 1–15 days; IQR = 9–14 days). A switch to 
oral antibiotics was made prior to (  N   = 5) or on the day of 
discharge (  N   = 10). All 15 children were discharged on oral 
amoxicillin-clavulanate, which was prescribed for a median 
of 7 weeks (range = 2–23 weeks; IQR = 4–13 weeks). One or 
more follow-up appointments were attended by 13 of 15 cases 1108 PAGNARITH AND OTHERS
 Figure 1.        Whole country map (  A  ) and zoomed view showing the place of residence (triangles) of 39 children with melioidosis presenting to the 
Angkor Hospital for Children (  B  ). H denotes this hospital.       1109 MELIOIDOSIS IN CAMBODIA
during antimicrobial therapy, and clinical features of infection 
were documented to have resolved in all of these cases. 
      Admitted with disseminated infection (  N   = 12).    The  seven 
attributable deaths in this group occurred before the culture 
results were available, and these patients were receiving 
ceftriaxone at the time of death. All 7 cases were admitted to 
the intensive care unit where management included ventilation 
for respiratory failure (  N   = 1), inotropes for circulatory failure 
(  N   = 2), or both treatment modalities (  N   = 4). Of note, two of 
four survivors in the disseminated group also had ventilatory 
failure requiring ventilation (1 case) or continous positive 
airway pressure (CPAP) therapy (1 case), and one of these 
cases also required inotropes. Empiric antimicrobial therapy 
(ceftiaxone) was also given to the four survivors before culture 
results, and after culture results were known, this therapy 
was followed by parenteral ceftazidime (1 case), amoxicillin-
clavulanate plus ceftriaxone (2 cases), or ciprofloxacin (1 case).  
The duration of parenteral therapy in this group ranged from 
10 to 31 days. Oral amoxicillin-clavulanate was given to all 
four cases after discharge and continued for between 5 and 23 
weeks. One or more follow-up appointments were attended 
by the four cases during this treatment period, and clinical 
features of infection were documented to have resolved in all 
of these cases. 
   Bacterial  genotyping.    The  39   B. pseudomallei   isolates from 
the study patients were resolved by MLST into 33 different 
STs (0.85 ST per isolate). Of these, 28 STs occurred one time, 
4 STs occurred two times, and one ST (ST 70) occurred three 
times. ST 70 is the most frequent clone isolated in Thailand 
and has also been identified previously in Laos and Hong 
Kong. Fourteen STs (42%) had not been identified previously 
and were unique to this study, one of which also included 
a novel allele at   gmhD  . The remaining 19 STs have been 
described previously in relation to isolates obtained from 
the environment and/or human disease in at least one Asian 
country. 
 Fourteen   B. pseudomallei   isolates cultured previously from 
soil in Cambodia were also examined using MLST, of which 12 
were isolated in Siem Reap province during 2006  12   and 2 were 
isolated in Phnom Penh in southern Cambodia in 1996. These 
were resolved into 14 different STs, including an additional 6 
unique STs that have not been described previously and were 
not represented in the invasive-strain collection described 
above. Of the remainder, four STs were also represented in 
the collection of 39 pediatric isolates, and four STs were not 
found in the pediatric collection but had been isolated previ-
ously in Asia. 
  The large number of STs found in this evaluation (including 
a total of 20 novel STs) is consistent with studies elsewhere in 
Asia and Australia,  17–  20   and is based on a high rate of recom-
bination of a pool of largely known alleles. A neighbor-joining 
tree was constructed using concatenated sequences of all 
seven loci for Cambodian invasive and soil isolates (  N   = 53) 
together with concatenated sequences downloaded from the 
MLST website (  www.mlst.net  ) for   B. pseudomallei   isolates 
from Thailand that had originated in our laboratory and/
or had been reported previously  17–  19   ( N   = 462). This showed 
that isolates from Cambodia and Thailand were highly related 
( Figure  2 ). 
     DISCUSSION 
  This is the first description of pediatric melioidosis in 
Cambodia. It was predicted that melioidosis would occur in 
our patient population, because the incidence of melioidosis 
in neighboring northeast Thailand is high.  5–  8    B. pseudomallei  
has been isolated from soil in the province of Siem Reap,  12  
 Table 1 
    Summary data for 39 children with melioidosis   
Variable Number
Male gender 15 38%
Age (years), median (range, IQR  *  ) 7.8 1.6–16.2; 4.1–12.4
Underlying disease present 4 10%
Source of   B. pseudomallei   isolate
Blood †  9 23%
Pus 29 74%
Respiratory secretions 1 3%




Acute suppurative parotitis 15 38%
Superficial soft-tissue abscess 7 18%
Blood culture positive and no 
focus identified 6 15%
Lymph-node abscess 4 10%
Pneumonia 3 8%
Meningitis 1 3%
Other §  3 8%
Admission WBC (×10  9   cells); 
median (range, IQR) 16.7 1.6–33.3; 9.6–20.7
Died during admission 8 21%
Death attributable to melioidosis 7 18%
Time to death (days); median (range) 2 day of admission 
to day 5
  *   IQR,  interquartile  range.  
  †   One  child  also  had   B. pseudomallei   isolated from urine   
    ‡     Localized infection was defined as a single, discrete culture-positive focus of infection in 
the absence a positive blood culture or clinical and/or microbiological evidence of dissemina-
tion to a second site. Disseminated infection was defined as the presence of infection in two 
or more discrete body sites and/or the presence of   B. pseudomallei   in blood.   
    §     Psoas muscle abscess (1 case), mastoiditis (1 case), and pharyngeal abscess (1 case).   
 Figure 2.        Neighbor-joining tree using concatenated sequences of 
all seven loci for Cambodian   B. pseudomallei   isolates from pediatric 
cases or soil (  N   = 53) together with concatenated sequences down-
loaded from the MLST website (  www.mlst.net  ) for   B. pseudomal-
lei   isolates from Thailand that had originated in our laboratory and/
or had been reported previously  18–  20   ( N   = 462). Red circles denote 
Cambodian isolates, and blue circles denote Thai isolates.       1110 PAGNARITH AND OTHERS
and seropositivity in the pediatric population has been already 
documented.  12   However, we are able to draw several impor-
tant lessons from our study. 
  This report highlights the value of diagnostic microbiol-
ogy in defining the epidemiology of infectious diseases in 
developing world settings. Patterns of infectious diseases and 
resistance rates of prevalent pathogens may vary both within 
and between countries, and microbiology provides relevant, 
region-specific information on which to base effective empiric 
antimicrobial prescribing policies. Information generated by 
diagnostic microbiology also provides a feedback loop to phy-
sicians on the accuracy of presumptive admission diagnoses. 
Melioidosis emerges when diagnostic microbiology facilities 
become available in areas where   B. pseudomallei   is present 
in the environment, but this is just one of many examples of 
the benefits associated with culture capabilities at the AHC. 
For example, we have recently identified children infected 
with multi-resistant community-associated methicillin resis-
tant   Staphylococcus aureus   (CA-MRSA) 21   and are currently 
defining rates of CA-MRSA carriage in the community. Our 
laboratory is also providing information for the region on the 
burden of childhood disease from vaccine-preventable infec-
tions such as those caused by   Streptococcus pneumoniae   and 
  Haemophilus influenzae . 
 The empiric antimicrobial drug of choice for children admit-
ted to the AHC with suspected bacterial infection is ceftriax-
one. This has broad-spectrum activity against a wide range of 
Gram-positive and Gram-negative bacteria, but is not recom-
mended for melioidosis. Current guidelines for the antimicro-
bial therapy of melioidosis are based on trials conducted in 
adult patients.  22–  24   They consist of an intensive phase of intra-
venous antimicrobial agents (ceftazidime or a carbapenem 
drug) for a minimum of 10–14 days followed by an eradica-
tion phase of oral antimicrobial agents (TMP-SMX with or 
without doxycycline or amoxicillin-clavulanate for pregnant 
women, children, or adults who cannot tolerate TMP-SMX) to 
complete a course of treatment lasting 12–20 weeks. A system-
atic evaluation of the antimicrobial therapy of children has not 
been published. This is an important knowledge gap, because 
localized infection may be cured with shorter courses of anti-
biotics, particularly when infection is mild and localized and a 
procedure is performed to drain pus. 
 Ceftriaxone and other cephalosporins, including cefotaxime, 
are active against   B. pseudomallei in vitro  . In a study of 100 
  B. pseudomallei   isolates from northern Australia, the min-
imum inhibitory concentration (MIC)  50      and  MIC 90   were 
4  μg/mL and 8 μg/mL, respectively, with a MIC range of 
2–8  μg/mL  25   (MIC for susceptible Gram-negative bacte-
ria is ≤ 8 μg/mL). The comparative MIC values for ceftazi-
dime in the same study were 2 μg/mL and 4 μg/mL for the 
MIC  50   and MIC  90  , respectively, with a range of 1–8 μg/mL  25  
(MIC for susceptible   B. pseudomallei   is  ≤ 8 μg/mL).  26   This 
suggests that ceftazidime may have an advantage over cef-
triaxone   in vivo  . The dose of ceftriaxone used at the AHC 
is 50–75 mg/kg given one time daily or in two divided doses. 
A possible disadvantage of one-time daily dosing is that the 
plasma concentration may fall below the MIC of the organ-
ism; average reported plasma concentrations in healthy adults 
24 hours after a single intravenous infusion of 0.5, 1, or 2 gm 
were reported to be 5, 9, and 15 μg/mL, respectively.  27   A  ret-
rospective review of empiric treatment in 1,353 adult patients 
with melioidosis in northeast Thailand reported that the mor-
tality rate in 528 patients given empiric ceftazidime therapy 
on admission was 41.7% compared with a mortality rate of 
71% in 167 patients who received cefotaxime or ceftriaxone.  28  
This study had several possible confounders; for example, the 
cefotaxime/ceftriaxone group had a higher rate of positive 
blood cultures than patients in the ceftazidime group, and this 
would be predicted to be associated with a higher death rate. 
However, this finding supports the use of ceftazidime in pref-
erence to other third-generation cephalosporins in patients 
with suspected or confirmed melioidosis. 
  Ceftazidime has been made available at the AHC and is 
now the parenteral treatment of choice for children with con-
firmed melioidosis, followed by a course of oral amoxicillin-
clavulanate. Deciding on best practice for empiric treatment 
is less clear cut, because melioidosis is rare (it accounted 
for 0.3% of all admissions during the study period), and 
  B. pseudomallei   ranks low on the list of bacterial pathogens 
isolated in our laboratory. Ceftriaxone would be the pre-
ferred choice over ceftazidime for several of the more com-
mon pathogens. Our current policy is to use ceftriaxone as the 
first-line empiric drug until culture results become available 
but to use ceftazidime or amoxicillin-clavulanate as the first-
line choice in children admitted with acute suppurative paro-
titis, in cases with multiple abscesses in the liver and/or spleen, 
and in cases suspected melioidosis based on other grounds. 
All deaths attributable to melioidosis occurred before cul-
ture results became available, and more rapid diagnostic tests 
are required to improve time to effective therapy. We are 
reviewing the turnaround time of culture results and the pos-
sibility of introducing a direct immunofluorescence test that 
can be used on pus and other material from suspected cases. 
This test can provide a presumptive same-day diagnosis and 
has a reported sensitivity and specificity of 66% and 99.5%, 
respectively.  29  
 The clinical features of the cases described here are very sim-
ilar to those described elsewhere in Asia. Childhood melioido-
sis is predominantly a disease of apparently immunocompetent 
persons, which contrasts with disease in adulthood when at least 
80% of those affected have at least one risk factor that affects 
host immunity. Our finding that two-thirds of disease was local-
ized is consistent with the published literature from Asia,  30–  34  
and the proportion of localized infections in the region of the 
head and neck is also consistent.  31,  33   A previous report describ-
ing acute suppurative parotitis in children caused by   B. pseudo-
mallei   in northeast Thailand suggested that this syndrome may 
prove to be a sensitive indicator of the presence of melioi-
dosis within a given geographic area.  9   This has proven to be 
the case for childhood infection in Asia, although this form of 
the disease is rare in Thai adults (occurring in 1% of adults 
with melioidosis in northeast Thailand) and is not observed 
in Australia.  35   We speculate that parotitis and infection of the 
regional lymph nodes of the neck may relate to the presence 
of contaminated water in the mouth related to bathing, swim-
ming, and drinking of untreated water, whereas localized infec-
tion of the lower limbs may relate to inoculation events. Overall 
death rates in previous pediatric case series have varied from 
10–38%, but common to all studies were the findings that no 
deaths occurred in children with localized disease and that bac-
teremia was associated with a high mortality rate.  30–  35   
  Melioidosis is not considered in the differential diagnosis in 
the majority of health-care settings in Cambodia, and the level 
of local knowledge about this condition is low. Commonly 1111 MELIOIDOSIS IN CAMBODIA
used empiric antimicrobial therapies will rarely include first-
line therapy for melioidosis. The identification of melioidosis 
at the AHC has led to an increased awareness and understand-
ing of this infection in our practice, and this will be followed by 
improvements in patient care. 
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